Organon & Co. will license exclusive global development, manufacturing and commercial rights to ebopiprant (OBE-022) from Obseva SA. Ebopiprant is a prostaglandin F2α receptor antagonist being developed for treating preterm labor by reducing inflammation and uterine contractions. Obseva could receive tiered double-digit royalties on commercial sales and as much as $500 million in up-front and milestone payments, including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million in sales-based milestones. Read More
New data on the addition of Infinity Pharmaceuticals Inc.'s oral PI3K-gamma inhibitor, eganelisib, to PD-(L)1 in both urothelial and triple-negative breast cancer patients appeared to evidence benefits for the combination. Benefit for company shares (NASDAQ:INFI), however, was nowhere to be seen, as they fell 31.5% to $1.52 on July 27. In a same-day earnings report, the Cambridge, Mass.-based company said it had a cash balance of $97.3 million to fund further development of the drug and filed to raise the maximum amount of capital it may raise in future sales of its shares. Read More
LONDON – Artios Ltd. has closed a $153 million series C, positioning it to intensify clinical development of its two lead programs, whilst applying its DNA damage response platform to exploit the full spectrum of vulnerabilities presented by inhibition of DNA damage repair enzymes. Read More
PERTH, Australia – Australia was one of the first nations to slam its borders shut during the pandemic, praising its efforts in containing COVID-19 infections. Read More
Hongyun Biotech Co. Ltd. raised ¥100 million (US$15.5 million) in a series B round to move its new generation EGFR inhibitor, RC-01, to the IND stage in China and the U.S. for non-small-cell lung carcinoma (NSCLC). The plan is to finish the IND filing by the end of this year and start the trial in 2022. Read More
With a special interest in neurological disorders, Hopstem Biotechnology Co. Ltd. closed a series A++ round to raise nearly ¥100 million (US$15.5 million) to advance hNPC-01, an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product to treat chronic conditions caused by stroke and traumatic brain injuries. Read More
New hires and promotions in the biopharma industry, including: Capricor, Centogene, Etherna, Eyegate, Hummingbird, Immunomet, Lava, Lumos, Poseida, Prokarium, Springworks, Synox. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Allegro Ophthalmics, Cassava, Da Volterra, GNT, Inmune, Iveric, Lee's, Radius, Sorrento, Synaptogenix, Tarsus, Tonix, Virios. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Abuse Deterrent, AC, Acura, Adagio, Affiris, Astrazeneca, Biocon, Brainstorm, Bridgebio, Bristol, Byondis, Calico, Deargen, Glycotope, Ionctura, Regeneration. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aadi, Abbvie, Alexion, Astrazeneca, Beigene, Beximco, Eledon, Fidia, GSK, Incyte, Inhibikase, Iterum, Kyowa Kirin, Neoimmunetech, Otsuka, Polarityte, Saniona. Read More